News

Only 25% of patients with indolent SM report their disease is well controlled, despite most clinicians believing control is common.

In systemic mastocytosis, mast cells release substances that disturb the normal balance of bone health and can lead to osteoporosis.

A recent study found that having SM may increase the risk of eclampsia but decrease the risk of abortive outcome in pregnancy.

EtCC plays a significant role in downregulating immune responses, which is important in diseases such as systemic mastocytosis.

Measuring levels of a chemical in the blood called diamine oxidase during anaphylaxis could help doctors diagnose patients with hidden SM.

Researchers describe a case of acute myeloid leukemia relapse occurring five years after an allogeneic stem cell transplant for SM-AHN.

If approved, dibutepinephrine could offer patients with SM a needle-free epinephrine option that is easier to carry and use.

The PATHFINDER clinical trial demonstrated that avapritinib leads to durable treatment responses and a favorable risk-benefit profile.

Researchers are currently recruiting patients for a trial assessing an investigational therapy for use in treatment-resistant blood cancer.

A new clinical trial published on ClinicalTrials.gov is underway to better understand how indolent SM affects people and how it is managed.